Zeneca and Sanofi each adding 250 reps to sales forces in 1997.
SANOFI ADDING 250 SALES REPS DURING 1997 to increase its field force from 400 to 650 in preparation for near-term product approvals and launches, the company reported Jan. 23. The expansion means that Sanofi will have more than tripled its sales force in the past two years: the company had 200 reps focused primarily on the hospital market before it acquired Bock Pharmacal in mid-1996 ("The Pink Sheet" July 22, 1996, p. 11).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth